SCHEMBL7253604

SCHEMBL7253604

CCC(N)(C(C)=O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
CYP1A2 P05177 2/20 0.41
KMT2A Q03164 2/20 0.41
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
ARG1 P05089 1/20 0.35
ARG2 P78540 1/20 0.35
GGT1 P19440 1/20 0.32
FFAR3 O14843 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
TSHR P16473 1/20 0.30
LCK P06239 1/20 0.30
FYN P06241 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11408094 0.86 ALDH1A1 (0.37) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL6882712 0.86 MEN1 (0.46) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL7320060 0.79 MEN1 (0.41) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL18036525 0.79 MEN1 (0.41) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL1005537 0.79 SMN1; SMN2 (0.37) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL31296136 0.79 SMN1; SMN2 (0.37) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL766735 0.77 SMN1; SMN2 (0.35) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL22612007 0.77 HIF1A (0.44) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL22612005 0.77 ALDH1A1 (0.40) ALDH1A1MEN1CYP1A2KMT2ATHRB
SCHEMBL16568741 0.77 MEN1 (0.40) ALDH1A1MEN1CYP1A2KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021106107-A1 MATERIAL AND COLUMN FOR COLLECTING CELLS HAVING RECOVERY FUNCTION OF HYPO-IMMUNE STATE 国立大学法人滋賀医科大学 2021-06-03 WO disclosed
CN-108349911-A Releasable nitric oxide production prodrugs 浙江华海药业股份有限公司 2018-07-31 CN disclosed
CN-104531794-B A kind of preparation method of the aminobutyric acid esters of N BOC D 2 浙江工业大学 2017-07-28 CN disclosed
EP-2697373-A1 PRODUCTION OF ENANTIOMERICALLY PURIFIED AMINO ACIDS Dr. Reddy's Laboratories (EU) Limited (GB) 2014-02-19 EP disclosed
WO-2012140507-A1 PRODUCTION OF ENANTIOMERICALLY PURIFIED AMINO ACIDS DR. REDDY'S LABORATORIES (EU) LIMITED (GB) 2012-10-18 WO disclosed
US-6573263-B2 For improving perception, concentration power, learning power and/ or memory power BAYER AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
US-20020198377-A1 Substituted imidazotriazinones BAYER AKTIENGESELLSCHAFT (DE) 2002-12-26 US disclosed
CN-1284086-A Conjugates useful in treatment of prostate cancer MERCK & CO INC (US) 2001-02-14 CN disclosed
US-4595532-A N-(substituted-methyl)-azetidin-2-ones UNIVERSITY OF NOTRE DAME DU LAC (US) 1986-06-17 US disclosed
EP-0116432-A2 Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones THE UNIVERSITY OF NOTRE DAME DU LAC (US) 1984-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198377-A1 Substituted imidazotriazinones CAMK4, ITPR1, KCNJ5 ALDH1A1 3498/4885MEN1 2751/4885CYP1A2 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.